755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICSPietro Lampertico, M. Colombo, R. Soffredini et al.|Journal of Hepatology|2013Cited by 24
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosisPietro Lampertico, M. Colombo, O. Fracassetti et al.|Digestive and Liver Disease|2014Cited by 23
OC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICEPietro Lampertico, M. Colombo, R. Soffredini et al.|Digestive and Liver Disease|2012Cited by 11
522 MAINTAINED VIRAL SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A 4-YEAR FIELD PRACTICE, MULTICENTER STUDYPietro Lampertico, M. Colombo, R. Soffredini et al.|Journal of Hepatology|2012Cited by 10
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovirMauro Viganò, Pietro Lampertico, Alessandro Loglio et al.|Liver International|2018Cited by 10